Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …

M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational new …, 2019 - Springer
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …
被引用次数：45 相关文章

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …

M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational New …, 2019 - infona.pl
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …

[引用][C] Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective …

M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational New …, 2019 - cir.nii.ac.jp
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung
cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) …

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …

M Tamiya, A Tamiya, K Hosoya… - Investigational …, 2019 - pubmed.ncbi.nlm.nih.gov
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …

M Tamiya, A Tamiya, K Hosoya… - Investigational New …, 2019 - search.proquest.com
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …

M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational new …, 2019 - europepmc.org
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …